Search results
Results from the WOW.Com Content Network
[6] [6] Peak concentrations of phentermine are reached 6 hours following oral administration of a dose of 15 mg. [6] The steady-state levels of phentermine with continuous administration have been found to be around 200 ng/mL in clinical studies. [6] The oral bioavailability of phentermine is not affected by intake of a high-fat meal. [6]
Phentermine is a substituted amphetamine and topiramate has an unknown mechanism of action Approved for weight management (short-term) by the FDA but not the European Medicines Agency [ 54 ] 10% [ 55 ] or 8.25 kilograms (18.2 lb) [ 56 ]
California has 8,015 pharmacies, the most of any state. Texas, Florida, New York, and Pennsylvania round out the top five states for pharmacy locations. [1] Nationwide, the number of community pharmacies increased by 6.3% between 2007-2015, and the number of pharmacies per 10,000 people (2.11) did not change.
Phentermine and topiramate was developed by Vivus, a California pharmaceutical company. In December 2009, Vivus, Inc. submitted a new drug application (NDA) to the FDA and on 1 March 2010, Vivus, Inc. announced that the FDA accepted the NDA for review.
Get AOL Mail for FREE! Manage your email like never before with travel, photo & document views. Personalize your inbox with themes & tabs. You've Got Mail!
Fen-phen (popular combination of fenfluramine and phentermine) 1997 Cardiotoxicity Fenclofenac: 1984 UK Cutaneous reactions; animal carcinogenicity. [3] Fenclozic acid: 1970 UK, US Hepatotoxicity. [3] Fenfluramine: 1997 European Union, UK, US, India, South Africa, others
Fenfluramine as a single drug was first introduced in the 1970s, but was not popular because it only temporarily reduced weight. [1] A 1984 study found a weight loss of 7.5 kg on average in 24 weeks, as compared to 4.4 kg under placebo. [4]
For maintenance of blood pressure in hypotensive states, the dose for adults is 30 to 45 mg as a single dose, repeated as necessary or followed by intravenous infusion of 0.1% mephentermine in 5% dextrose, with the rate and duration of administration depending on the patient's response.